USS Investment Management Ltd lessened its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 20.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 13,400 shares of the company’s stock after selling 3,400 shares during the period. USS Investment Management Ltd’s holdings in Neurocrine Biosciences were worth $1,902,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of the stock. Parallel Advisors LLC lifted its position in Neurocrine Biosciences by 3.5% in the 3rd quarter. Parallel Advisors LLC now owns 1,780 shares of the company’s stock valued at $252,000 after acquiring an additional 61 shares in the last quarter. NewEdge Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 0.5% in the 1st quarter. NewEdge Advisors LLC now owns 13,066 shares of the company’s stock valued at $1,721,000 after acquiring an additional 68 shares in the last quarter. Entrust Financial LLC increased its position in shares of Neurocrine Biosciences by 62.9% in the third quarter. Entrust Financial LLC now owns 202 shares of the company’s stock valued at $29,000 after acquiring an additional 78 shares during the last quarter. Keybank National Association OH grew its stake in Neurocrine Biosciences by 4.7% in the third quarter. Keybank National Association OH now owns 2,001 shares of the company’s stock valued at $284,000 after purchasing an additional 89 shares in the last quarter. Finally, Meiji Yasuda Life Insurance Co increased its position in shares of Neurocrine Biosciences by 1.8% during the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 5,628 shares of the company’s stock worth $949,000 after purchasing an additional 100 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.
Neurocrine Biosciences Price Performance
NASDAQ:NBIX opened at $150.57 on Friday. The company has a market cap of $15.24 billion, a PE ratio of 22.34, a P/E/G ratio of 0.61 and a beta of 0.36. The firm’s 50 day simple moving average is $149.03 and its 200 day simple moving average is $149.49. Neurocrine Biosciences, Inc. has a one year low of $122.14 and a one year high of $186.12.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last released its earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. The business had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.04 billion. Neurocrine Biosciences had a return on equity of 23.39% and a net margin of 18.98%. The firm’s revenue was up 41.3% on a year-over-year basis. During the same quarter last year, the firm posted $2.04 earnings per share. Equities research analysts expect that Neurocrine Biosciences, Inc. will post 8.41 EPS for the current year.
Insider Transactions at Neurocrine Biosciences
In related news, Director George Morrow sold 7,500 shares of the stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $145.79, for a total value of $1,093,425.00. Following the completion of the sale, the director directly owned 10,386 shares of the company’s stock, valued at approximately $1,514,174.94. This represents a 41.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Matt Abernethy sold 2,311 shares of the stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the sale, the chief financial officer owned 42,808 shares of the company’s stock, valued at approximately $6,729,417.60. This trade represents a 5.12% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 18,137 shares of company stock valued at $2,829,332 over the last ninety days. 4.60% of the stock is owned by company insiders.
Analyst Ratings Changes
A number of brokerages recently weighed in on NBIX. Zacks Research downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. Cantor Fitzgerald boosted their price target on Neurocrine Biosciences from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Truist Financial raised their price objective on Neurocrine Biosciences from $200.00 to $213.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Morgan Stanley increased their price target on Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a research note on Friday, November 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $204.00 price target on shares of Neurocrine Biosciences in a report on Friday, October 16th. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $202.59.
View Our Latest Stock Analysis on Neurocrine Biosciences
Neurocrine Biosciences Profile
Neurocrine Biosciences is a biopharmaceutical company focused on developing and commercializing treatments for neurological, endocrine and related disorders. Founded in 1992 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed medicines include INGREZZA (valbenazine), approved in the United States for tardive dyskinesia and chorea associated with Huntington disease, and CRENESSITY (crinecerfont), used with glucocorticoid replacement therapy to treat classic congenital adrenal hyperplasia in adults and children.
Read More
- Five stocks we like better than Neurocrine Biosciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
